Table 1.

Tumor incidence, multiplicity and histopathology

Site and type of tumor†	Incidence (%)		(Multiplicity (no. tumors/mouse)
	DMAV, 200 p.p.m.	Control	DMAV, 200 p.p.m.	Control
Ogg1 −/–
No. mice	10	10	10	10
No. tumor bearing mice (%)	10 (100%)**, ***	0
M. lymphoma/leukemia	4 (40)	0	0.4 ± 0.5	0
Liver
HCC	1 (10)	0	0.1 ± 0.31	0
Lung
Hyperplasia	10 (100)	10 (100)	5.0 ± 1.0*, ****	6.8 ± 1.09
Adenoma	2 (20)	0	0.2 ± 0.42	0
Adenocarcinoma	3 (30)	0	0.3 ± 0.48	0
Total tumors	5 (50)*, ***	0	0.5 ± 0.52*, ***	0
Mammary gland	1 (10)	0	0.1 ± 0.3	0
Adenocarcinoma
Ogg1 +/+
No. mice	12	10	12	10
No. tumor bearing mice (%)	6 (50%)	5 (50%)
M. lymphoma/leukemia	2 (16.7)	2 (20)	0.17 ± 0.38	0.2 ± 0.3
Liver
HCC	1 (8.3)	0	0.08 ± 0.28	0
Lung
Hyperplasia	10 (100)	2 (20)	3.00 ± 2.76*	0.33 ± 0.10
Adenoma	0	1 (10)	0	0.10 ± 0.31
Adenocarcinoma	0	0	0	0
Total tumors	0	1 (10)	0	0.10 ± 0.31
Mammary gland
Adenocarcinoma	1 (8.3)	0	0.08 ± 0.28	0
Renal
Adenocarcinoma	1 (8.3)	0	0.08 ± 0.28	0
Subcutis
Fibrosarcoma	0	1 (10)	0	0.1 ± 0.31
Skin
Sarcoma	1 (8.3)	0	0.08 ± 0.28	0

^† Only organs with neoplastic lesions are listed.

^* P < 0.05,

^** P < 0.0001 versus corresponding non‐treated controls;

^*** P < 0.05,

^**** P < 0.0001 versus Ogg1 ^+/+ DMA^V‐treated or control groups. DMA^V, dimethylarsinic acid; HCC; hepatocellular carcinoma; M. lymphoma, malignant lymphoma.